SCHEMBL2594701

SCHEMBL2594701

CCCCCCCCC=CCCCCCCCC#N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.56
FAAH O00519 4/20 0.52
TRPV1 Q8NER1 1/20 0.52
TERT O14746 3/20 0.45
PTPN1 P18031 3/20 0.45
PPARG P37231 3/20 0.45
PPARD Q03181 3/20 0.45
PPARA Q07869 3/20 0.45
CYP1A2 P05177 2/20 0.45
MAPT P10636 2/20 0.45
CYP2C19 P33261 2/20 0.45
BLM P54132 2/20 0.45
HSD17B10 Q99714 2/20 0.45
FABP4 P15090 2/20 0.45
KMT2A Q03164 2/20 0.45
TOP1 P11387 2/20 0.45
GMNN O75496 1/20 0.45
USP2 O75604 1/20 0.45
LMNA P02545 1/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11854516 1.00 TSHR (0.56) TSHRFAAHTRPV1TERTPTPN1
SCHEMBL11855357 1.00 TSHR (0.56) TSHRFAAHTRPV1TERTPTPN1
SCHEMBL11853973 1.00 TSHR (0.56) TSHRFAAHTRPV1TERTPTPN1
SCHEMBL11855060 1.00 TSHR (0.56) TSHRFAAHTRPV1TERTPTPN1
SCHEMBL11854121 1.00 TSHR (0.56) TSHRFAAHTRPV1TERTPTPN1
SCHEMBL22296738 1.00 TSHR (0.56) TSHRFAAHTRPV1TERTPTPN1
SCHEMBL25254569 1.00 TSHR (0.56) TSHRFAAHTRPV1TERTPTPN1
SCHEMBL11855054 1.00 TSHR (0.56) TSHRFAAHTRPV1TERTPTPN1
SCHEMBL22296755 1.00 TSHR (0.56) TSHRFAAHTRPV1TERTPTPN1
SCHEMBL11849882 1.00 TSHR (0.56) TSHRFAAHTRPV1TERTPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4687453-A1 BIOSTIMULANT COMPOSITION Tenfold Technologies, LLC (US) 2026-02-11 EP claimed
CN-111208029-B Method for evaluating ecotoxicity of organic additive in full-biodegradable mulching film by applying water culture experiment 贵州省烟草科学研究院 2022-12-09 CN claimed
CN-111948301-B Qualitative and quantitative analysis method for organic additives in full-biodegradable mulching film 贵州省烟草科学研究院 2022-11-29 CN claimed
EP-2941413-B1 PROCESS FOR THE SYNTHESIS OF OMEGA-UNSATURATED NITRILE-ACID/ESTER IN WHICH TWO TYPES OF CROSS METATHESIS ARE ALTERNATED CONSECUTIVELY, SWING PROCESS ARKEMA FRANCE (FR) 2016-10-19 EP claimed
EP-2566842-B1 PROCESS FOR PREPARING SATURATED AMINO ACIDS OR SATURATED AMINO ESTERS COMPRISING A METATHESIS STEP ARKEMA FRANCE (FR) 2016-05-04 EP claimed
CN-103140471-B Comprise the method for the preparation of saturated amino acid or saturated amino ester of autometathesis step ARKEMA FRANCE (FR) 2016-03-09 CN claimed
US-20150336879-A1 PROCESS FOR THE SYNTHESIS OF OMEGA-UNSATURATED NITRILE-ACID/ESTER IN WHICH TWO TYPES OF CROSS METATHESIS ARE ALTERNATED CONSECUTIVELY, SWING PROCESS ARKEMA FRANCE (FR) 2015-11-26 US claimed
EP-2941413-A1 PROCESS FOR THE SYNTHESIS OF OMEGA-UNSATURATED NITRILE-ACID/ESTER IN WHICH TWO TYPES OF CROSS METATHESIS ARE ALTERNATED CONSECUTIVELY, SWING PROCESS Arkema France (FR) 2015-11-11 EP claimed
CN-104884428-A Process for the synthesis of omega-unsaturated nitrile-acids/esters, PROCEDE SWING, in which two types of cross-metathesis are successively alternated ARKEMA FRANCE 2015-09-02 CN claimed
US-9096490-B2 Process for preparing saturated amino acids or saturated amino esters comprising a metathesis step ARKEMA FRANCE (FR) 2015-08-04 US claimed
WO-2014106766-A1 PROCESS FOR THE SYNTHESIS OF OMEGA-UNSATURATED NITRILE-ACID/ESTER IN WHICH TWO TYPES OF CROSS METATHESIS ARE ALTERNATED CONSECUTIVELY, SWING PROCESS ARKEMA FRANCE (FR) 2014-07-10 WO claimed
EP-2729456-A1 PREPARATION OF NITRILE COMPOUNDS DSM IP Assets B.V. (NL) 2014-05-14 EP claimed
CN-103140471-A Process for preparing saturated amino acids or saturated amino esters comprising a metathesis step ARKEMA FRANCE 2013-06-05 CN claimed
US-20130116458-A1 PROCESS FOR PREPARING SATURATED AMINO ACIDS OR SATURATED AMINO ESTERS COMPRISING A METATHESIS STEP ARKEMA FRANCE (FR) 2013-05-09 US claimed
EP-2566842-A1 PROCESS FOR PREPARING SATURATED AMINO ACIDS OR SATURATED AMINO ESTERS COMPRISING A METATHESIS STEP Arkema France (FR) 2013-03-13 EP claimed
WO-2013007634-A1 PREPARATION OF NITRILE COMPOUNDS DSM IP ASSETS B.V. (NL) 2013-01-17 WO claimed
WO-2011138051-A1 PROCESS FOR PREPARING SATURATED AMINO ACIDS OR SATURATED AMINO ESTERS COMPRISING A METATHESIS STEP ARKEMA FRANCE (FR) 2011-11-10 WO claimed
US-6107370-A COATING MATERIAL CONSISTS OF AN EPOXY RESIN, A SILANOL BASED POLYDIMETHYLSILOXANE, AN AMINE FUNCTIONAL SILICON POLYMER, A DISTILLED FATTY NITRILE; CHEMICAL RESISTANCE COTAING AEGIS COATING TECHNOLOGIES (US) 2000-08-22 US claimed
US-4217299-A Method for converting unsaturated compound having functional group JAPAN SYNTHETIC RUBBER CO., LTD. (JP) 1980-08-12 US claimed
US-3974196-A Method for disproportionating ethylenically unsaturated compounds having functional ester groups JAPAN SYNTHETIC RUBBER CO., LTD. (JA) 1976-08-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116458-A1 PROCESS FOR PREPARING SATURATED AMINO ACIDS OR SATURATED AMINO ESTERS COMPRISING A METATHESIS STEP METTL14, MAX, AADAT TSHR 4003/4885FAAH 608/4885TRPV1 4037/4885
US-20150336879-A1 PROCESS FOR THE SYNTHESIS OF OMEGA-UNSATURATED NITRILE-ACID/ESTER IN WHICH TWO TYPES OF CROSS METATHESIS ARE ALTERNATED CONSECUTIVELY, SWING PROCESS FASN, METTL14, ALOX12 TSHR 4629/4885FAAH 83/4885TRPV1 4451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.